Please ensure Javascript is enabled for purposes of website accessibility

Sustainability Pays: 3 Green Companies Making Money

By Selena Maranjian – Oct 16, 2014 at 11:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Green companies needn't settle for sub-par performances, because sustainability can be profitable.


Photo: Flickr user Kevin Dooley.

We often imagine that for companies, there's a trade-off between being profitable and being green. We assume that maximum profitability is achieved by ignoring the environment and that green companies have to settle for mediocre performance while doing right. That's all wrong, though. A glance at Newsweek's 2014 list of the greenest companies includes plenty of strong performers, suggesting that sustainability pays.

Check out the top 10:

Rank

Company

Average Annual Return Over Past 10 Years

1

Allergan

18.6%

2

Adobe Systems Incorporated 

9.8%

3

Ball Corporation 

13.3%

4

Ecolab 

13.5%

5

Sigma-Aldrich Corporation 

17.4%

6

McCormick & Company 

8.5%

7

Biogen Idec Inc 

18.3%

8

Rockwell Automation 

11.3%

9

Cardinal Health Inc 

10.4%

10

Agilent Technologies 

10.1%

 

S&P 500

7.7%

Source: Newsweek, Morningstar. 

All 10 green companies had 10-year performances that topped the S&P 500. Clearly, they're not suffering too much while engaging in environmentally friendly practices. Their track records certainly support the notion that sustainability pays.

Let's take a closer look at a handful of these companies to get an idea of what makes them green and to roughly assess their attractiveness as investments.

Cardinal Health
Cardinal Health
(CAH 0.24%) offers pharmaceutical and medical products and services to healthcare companies around the world, helping them improve efficiency and profitability. It has been growing its own profit margins in recent years, along with its free cash flow, which tops $2.2 billion annually. In its own words, "Cardinal Health sustainability initiatives focus on pollution prevention, energy efficiency, waste reduction, and designing products, packaging and services to be environmentally friendly." Its surgical gloves, for example, are sold in half-fold packaging: The dispenser boxes require at least 15% less cardboard and take up at least 30% less room, and the individual pouches are at least 48% smaller than alternatives. About 95% of the glove-wrapping material is made from recyclable and renewable sources.

Cardinal's stock valuation is appealing, with both its recent and forward-looking P/E ratios (22 and 18, respectively) below the five-year average of 23. One potential business catalyst, however grim, is the Ebola outbreak, which is requiring lots of protective gear. Cardinal is also partnering with CVS Health to boost both companies' positions in generic drugs.

Biogen Idec
Biogen Idec
(BIIB -0.17%) is also intriguing, with a P/E ratio of 32 well above its five-year average of 23 and a forward P/E of 19 well below the average. The discrepancy is due to expectations of rapid growth -- to the tune of 40% over the next year. Its past growth has been impressive, with revenue doubling over the past six years and net income growing almost 10-fold over the past eight years. The company is a leader in treating multiple sclerosis, with drugs such as Avonex, Tecfidera, and Tysabri. Its free cash flow of more than $2.3 billion gives it the flexibility to add to its pipeline.

Regarding sustainability, the company itself explains:

Our strategic approach to environmental sustainability focuses on three key areas: water, energy and materials. In 2009, we set a long-term goal of reducing our overall environmental footprint by 15 percent by 2015, compared to 2006 levels. We reached our 2015 goals in 2012, reducing our environmental footprint by 18 percent, and have established bold new goals for 2020. 

Allergan
Allergan
(NYSE: AGN) is yet another green company in the broad healthcare arena. This specialty pharmaceutical company, whose product stable includes Botox, is currently the subject of much activist-investor attention, with some demanding that it merge with Valeant Pharmaceuticals to create a large company specializing in eye- and skin-care drugs. As my colleague George Budwell has pointed out, buyout speculation has sent the shares skyrocketing, but Allergan itself isn't in favor of a combination, as it expects to grow plenty fast on its own.

Sustainability-wise, like many companies, Allergan posts a lot of goals and results on its website, noting, for example, that between 2012 and 2013, it reduced energy use by 2.3% and reduced hazardous waste by 12%. In addition, "Allergan increased its recycling rate from 29% in 1995 to 76% in 2013." Not every metric measured was positive, but the company is clearly paying attention to its performance and aiming to improve.

Longtime Fool specialist Selena Maranjian, whom you can follow on Twitter, has no position in any stocks mentioned. The Motley Fool recommends Adobe Systems, CVS Health, and Valeant Pharmaceuticals. The Motley Fool owns shares of Ecolab and Valeant Pharmaceuticals. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cardinal Health Stock Quote
Cardinal Health
CAH
$78.65 (0.24%) $0.19
Biogen Stock Quote
Biogen
BIIB
$291.41 (-0.17%) $0.49

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
351%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.